Dr. Michael G. Hanna, Jr. A pioneer in active specific immunotherapy of cancer. He received his PhD in experimental pathology and immunology from the University of Tennessee (TN, USA) in the 1960s. Dr. Hanna served during 1974–83 as Director of the National Cancer Institute, Frederick Cancer Research Center (MD, USA). In 2007, he founded Vaccinogen Inc., where he served as Chairman and CEO. Dr. Hanna’s research resulted in over 225 publications in international peer-reviewed journals and book chapters, and he holds 10 patents related to immunotherapy.